Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
AssigneeThe University of Queensland
InventorsMichelle Mei Chih HILL, Alok SHAH, Kim-Ahn Lê CAO
Life of this patent
Estimating the term…
Abstract
Disclosed are biomarkers for Barrett's esophagus and esophageal adenocarcinoma, and uses thereof, such as in methods for detecting the presence, and monitoring progression, of Barrett's esophagus and esophageal adenocarcinoma. Also disclosed are methods for treating and methods of monitoring the treatment of Barrett's esophagus and esophageal adenocarcinoma, as well as kits and compositions for use in such methods.
Claims26
1-54. (canceled)
A composition comprising a biological sample from a subject having or suspected of having Barrett's esophagus (BE) or esophageal adenocarcinoma (EAC) comprising a glycospecies of at least one glycoprotein;
- and one or more reagents for determining the level of said glycospecies, wherein the at least one glycoprotein comprises complement C9.
A method of treating esophageal adenocarcinoma (EAC) in a subject, comprising:
- a) determining in a sample from the subject the level of a glycospecies of at least one glycoprotein, which glycospecies is differentially expressed between EAC and one or more other conditions selected from healthy condition (HC) and Barrett's esophagus (BE), and determining a likelihood of the subject having EAC based on whether the respective levels of the individual glycospecies are above or below a corresponding predetermined threshold that correlates with the presence of EAC, wherein the at least one glycoprotein comprises complement C9;
- and
- b) exposing the subject to a treatment regimen for EAC.
Dependencies are inferred from the claim text.